Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Enhancing immune checkpoint delivery to diffuse midline glioma (DMG) using focused ultrasound [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...

as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). Median overall survival, the primary outcome measure, was 23.7 months in those randomized to ...

The trial compared the combo against the investigator’s choice of tyrosine kinase inhibitor monotherapy in the unresectable or advanced hepatocellular carcinoma patient group. Credit: ...

advantages and the application of dynamic PET/CT imaging in malignant tumors, including lung cancer, hepatocellular carcinoma, breast cancer, pancreatic carcinoma, prostate neoplasm, and cancer of ...

Abstract: Diffuse optical imaging (DOI) offers valuable insights into scattering mediums, but the quest for high-resolution imaging often requires dense sampling strategies, leading to higher imaging ...

The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This regulatory decision is ...